Cell Lines as Candidate Reference Materials for Quality Control of ERBB2 Amplification and Expression Assays in Breast Cancer

被引:38
作者
Xiao, Yan [1 ]
Gao, Xiugong [3 ]
Maragh, Samantha
Telford, William G. [4 ]
Tona, Alessandro [2 ]
机构
[1] Natl Inst Stand & Technol, DNA Measurements Grp, Div Biochem Sci, Chem Sci & Technol Lab, Gaithersburg, MD 20899 USA
[2] Sci Applicat Int Corp, Arlington, VA USA
[3] Translabion, Clarksburg, MD USA
[4] NCI, Expt Transplantat & Immunol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
关键词
HER-2/NEU EXPRESSION; ESTROGEN-RECEPTOR; HER2; IMMUNOHISTOCHEMISTRY; QUANTITATION; C-ERBB-2; STANDARD; GENE; TIME;
D O I
10.1373/clinchem.2008.120576
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
BACK(;ROUND: Human epidermal growth factor receptor 2 (HER2) is an important biomarker whose status plays a pivotal role in therapeutic decision-making for breast cancer patients and in determining their clinical outcomes. Ensuring the accuracy and reproducibility of HER2 assays by immunohistochemistry (IHC) and by fluorescence in situ hybridization (FISH) requires a reliable standard for monitoring assay sensitivity and specificity, and for assessing methodologic variation. A prior NIST workshop addressed this need by reaching a consensus to create cell lines as reference materials for HER2 testing. METHODS: Breast carcinoma cell lines SK-BR-3 and MCF-7 were characterized quantitatively by IHC with chicken anti-HER2 IgY antibody and by FISH with biotinylated bacterial artificial chromosome DNA probes; both assays used quantum dots as detectors. Formalin-fixed and paraffin-embedded (FFPE) cell blocks were prepared and tested for suitability as candidate reference materials by IHC and FISH with commercially available reagents. IHC and FISH results were also compared with those obtained by laser-scanning cytometry and real-time PCR, respectively. RESULTS: MCF-7 cells had typical numbers of gene copies and very low production of HER2 protein, whereas SK-BR-3 cells contained approximately 10-fold more copies of the gene and exhibited approximately 15-fold higher amounts of HER2 protein than MCF-7 cells. FFPE SK-BR-3 cells showed results similar to those for fresh SK-BR-3 cells. CONCLUSIONS: SK-BR-3 and MCF-7 are suitable as candidate reference materials in QC of HER2 testing. Coupled with the associated assay platforms, they provide valuable controls for quantitative measurement of HER2 amplification and production in breast cancer samples, irrespective of the antibody/probe or detector used. (C) 2009 American Association for Clinical Chemistry
引用
收藏
页码:1307 / 1315
页数:9
相关论文
共 24 条
[1]   THE PRODUCT OF THE HUMAN C-ERBB-2 GENE - A 185-KILODALTON GLYCOPROTEIN WITH TYROSINE KINASE-ACTIVITY [J].
AKIYAMA, T ;
SUDO, C ;
OGAWARA, H ;
TOYOSHIMA, K ;
YAMAMOTO, T .
SCIENCE, 1986, 232 (4758) :1644-1646
[2]  
ALLRED DC, 1993, AM J CLIN PATHOL, V99, P1
[3]  
Bánkfalvi A, 2004, INT J ONCOL, V25, P929
[4]   Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].
Cobleigh, MA ;
Vogel, CL ;
Tripathy, D ;
Robert, NJ ;
Scholl, S ;
Fehrenbacher, L ;
Wolter, JM ;
Paton, V ;
Shak, S ;
Lieberman, G ;
Slamon, DJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648
[5]   Oestrogen receptors and breast cancer - It is time for individualised treatment based on oestrogen receptor status [J].
Elledge, RM ;
Osborne, CK .
BRITISH MEDICAL JOURNAL, 1997, 314 (7098) :1843-1844
[6]  
Hammond MEH, 2003, APPL IMMUNOHISTO M M, V11, P103
[7]   Heart of darkness: The downside of trastuzumab [J].
Hayes, Daniel F. ;
Picard, Michael H. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (25) :4056-4058
[8]   Determination of Her-2/neu status in breast carcinoma:: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization [J].
Jimenez, RE ;
Wallis, T ;
Tabasczka, P ;
Visscher, DW .
MODERN PATHOLOGY, 2000, 13 (01) :37-45
[9]  
Morgan J., 2001, J CELLULAR PATHOLOGY, V5, P171
[10]   Real-world performance of HER2 testing - National surgical adjuvant breast and bowel project experience [J].
Paik, S ;
Bryant, J ;
Tan-Chiu, E ;
Romond, E ;
Hiller, W ;
Park, K ;
Brown, A ;
Yothers, G ;
Anderson, S ;
Smith, R ;
Wickerham, DL ;
Wolmark, N .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (11) :852-854